ABBV ▼ -1.2% - AbbVie Inc.
$ABBV - AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
30-SEP-2026 01:30 AM ET
Share this post
More filings for $ABBV
ABBV ▼ -1.2% - AbbVie Inc.Sep 30, 2026ABBV ▲ +0.0% - AbbVie Inc.Sep 29, 2026ABBV ▼ -0.2% - AbbVie Inc.Sep 22, 2026ABBV ▲ +0.5% - AbbVie Inc.Sep 22, 2026ABBV ▼ -0.7% - AbbVie Inc.Sep 21, 2026ABBV ▼ -0.1% - AbbVie Inc.Sep 18, 2026
View full $ABBV filing history →💬 Comments
Loading comments…
Leave a comment